Dabigatran Chemical Properties

Melting point:

268-272°C

Boiling point:

797.1±70.0 °C(Predicted)

Density 

1.38±0.1 g/cm3(Predicted)

storage temp. 

Keep in dark place,Inert atmosphere,Room temperature

solubility 

Aqueous Acid

form 

Solid

pka

4.17±0.10(Predicted)

color 

White to Brown

Safety Information

Hazardous Substances Data

211914-51-1(Hazardous Substances Data)

Dabigatran Usage And Synthesis

Chemical Properties

Tan Solid

Uses

BIBR 953 (Dabigatran, Pradaxa) is potent nonpeptide thrombin inhibitor with an IC50 of 9.3 nM

Uses

Nonpeptide, direct thrombin inhibitor. Antithrombotic.

Definition

ChEBI: An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-b ta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism.

Biological Activity

bibr 953 is a potent, reversible, and direct inhibitor of thrombin with ic50 value of 9.3nm [1].bibr 953 shows a favorable selectivity profile and strong activity in vitro with a ki value of 4.5nm. it also exhibits the best activity profile in vivo following administration to rats. bibr 953 is designed to be converted into an orally active prodrug bibr 1048 due to its highly polar, zwitterionic nature and poor oral absorption. bibr 953 inhibits thrombin in a competitive fashion. this inhibition is rapid and reversible. bibr 953 inhibits both clot-bound and free thrombin. bibr 953 is demonstrated to have an anticoagulant efficacy both in vitro and ex vivo. since thrombin can affect cell behavior and response in various tissue types via par signaling, bibr 953 is found to be beneficial in many diseases including inflammation, infection, fibrosis and cancer.

target

thrombin

References

[1] hauel nh, nar h, priepke h, ries u, stassen jm, wienen w. structure-based design of novel potent nonpeptide thrombin inhibitors. j med chem. 2002 apr 25;45(9):1757-66.
[2] van ryn j, goss a, hauel n, wienen w, priepke h, nar h, clemens a. the discovery of dabigatran etexilate. front pharmacol. 2013 feb 12;4:12.

Dabigatran(211914-51-1)Related Product Information

• Rivaroxaban
• Dabigatran etexilate
• Dabigatran Etexilate Mesylate
• 4-methoxy-N-methyl-3-nitrobenzamide
• 3-[[[2-[[(4-Cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridin-2-ylamino]propionic acid ethyl ester
• N-(4-CYANO-PHENYL)-GLYCINE
• Chloroacetic anhydride
• 4-Aminobenzamidine dihydrochloride
• 3-[(3-AMINO-4-METHYLAMINO-BENZOYL)-PYRIDIN-2-YL-AMINO]-PROPIONIC ACID ETHYL ESTER
• HEXYL CHLOROFORMATE
• N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-(2-pyridinyl)-beta-alanine ethyl ester hydrochloride
• Bortezomib
• Y27632 (hydrochloride)
• (+)-JQ1
• Apixaban
• Dabigatran iMpurity K
• Dabigatran iMpurity D
• Des-(N-2-pyridyl-β-alanine Ethyl Ester) Dabigatran Etexilate 5-Ethyl Carboxylate (Dabigatran IMpurity)